AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31622885
Drug: Allogeneic PRP
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic PRP treatment
Trial: 31438858
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous bone marrow mononuclear cells (BMMNCs)
Trial: 28786105
Drug: Low-dose 13-cis
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose 13-cis retinoic acid (7.5 mg or 10 mg) for 2 years
Trial: 26418022
Drug: ivabradine 7.5
RxNorm normalized name: ivabradine 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 7.5 mg BID
Trial: 21788309
Drug: PIEB (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIEB (10 mL every hour beginning 60 minutes after the initial dose)
Trial: 21788309
Drug: CEI (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEI (10 mL/h, beginning immediately after the initial dose)
Trial: 17088770
Drug: Auto-cross-linked hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auto-cross-linked hyaluronic acid gel (group A, 30 patients)
Trial: 10997402
Drug: Three-times-daily indinavir
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-times-daily indinavir (800 mg every 8 h or 1200 mg every 12 h) with zidovudine (300 mg) and lamivudine (150 mg) every 12 h
Trial: 10997402
Drug: Two-times-daily indinavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-times-daily indinavir (800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h) with zidovudine (300 mg) and lamivudine (150 mg) every 12 h
Trial: 1591370
Drug: Protein A
RxNorm normalized name: Protein antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein A perfusion in cancer chemotherapy-related hemolytic-uremic syndrome
Trial: 4054140
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg TID for 1 week
Trial: 4054140
Drug: Prazosin 1
RxNorm normalized name: prazosin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 1 mg TID for 1 week
Trial: 23904009
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (N=13)
Trial: 21396214
Drug: Oral amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin/clavulanate 30 min before bronchoscopy
Trial: 14749008
Drug: Hypothermia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia group (HG); rectal temperature = 34.5 degrees C +/‐ 0.3 degrees C, nasopharyngeal temperature = 34.0 degrees C +/‐ 0.5 degrees C, n = 23
Trial: 6150050
Drug: C6/36 sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C6/36 sham vaccine (intraderma tests)
Trial: 3927959
Drug: Nicardipine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 120 mg day-1
Trial: 22490629
Drug: Intensive antiplatelet
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive antiplatelet therapy
Trial: 16339055
Drug: Multivitamin supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplements
Trial: 20536472
Drug: Synthetic thymosin
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic thymosin beta4 (Tbeta4) 42-1260 mg, administered intravenously, single dose and daily for 14 days
Trial: 10839287
Drug: DBPT chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPT chemotherapy (dacarbazine, BCNU, cisplatin, and tamoxifen)
Trial: 10839287
Drug: DTIC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC chemotherapy
Trial: 8971427
Drug: Captopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (2 x 25 mg day‐1)
Trial: 8971427
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) (1 x 100 mg day‐1)
Trial: 8971427
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of captopril and ASA
Trial: 8839527
Drug: Rectal temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal temperature measurement
Trial: 26079743
Drug: Intensive antiplatelet
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) for one month
Trial: 26079743
Drug: Guideline antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline antiplatelet therapy for one month
Trial: 15044693
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ATRA and As(2)O(3)
Trial: 16960167
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (17.6 mL/d, 1.8 g 20:5n-3, 3.0 g 22:6n-3, 5.9 g total n-3 fatty acids)
Trial: 16960167
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (17.8 mL/d, 8.5 g 18:2n-6)
Trial: 11722118
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin administration
Trial: 9930635
Drug: Fluoxetine (FX)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FX) 20 mg/day (n=67)
Trial: 9930635
Drug: Amitriptyline (AM)
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline (AM) daily dose: 115+/‐39.2mg (n=75)
Trial: 9930635
Drug: Fluoxetine (FX)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FX)
Trial: 2921588
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 1.5 mg/70 kg
Trial: 28240013
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy with biofeedback training
Trial: 28240013
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy without biofeedback training (Control)
Trial: 25409877
Drug: Light salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light salt (3 g daily for 4 weeks)
Trial: 25409877
Drug: Regular salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular salt (3 g daily for 4 weeks)
Trial: 23898483
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb761) 100 mg/kg orally, pre-treated 10 days before and 5 days after ADR treatment
Trial: 23898483
Drug: Adriamycin (ADR)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADR) 20 mg/kg i.p.
Trial: 20204604
Drug: Daily cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cholecalciferol 800 IU + calcium 1,000 mg for 3 years
Trial: 16630670
Drug: Gemcitabine 10
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 10 mg/m2/min for 150 min on days 1 and 8 every 3 weeks by intravenous infusion at fixed dose rate (arm B)
Trial: 29072016
Drug: Simple kegel
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple kegel exercise therapy
Trial: 18165850
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (EGb761) 120 mg twice per day
Trial: 12928941
Drug: Anakinra (Kineret®)
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra (Kineret®) combined with anti-TNF agents
Trial: 2113258
Drug: Kaolin-pectin solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaolin-pectin solution, diphenhydramine plus saline (KBS)
Trial: 483371
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment in addition to a standard regime
Trial: 483371
Drug: Standard regime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regime without steroids
Trial: 28547735
Drug: Probable Medication-Overuse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probable Medication-Overuse Headache (pMOH)
Trial: 19573383
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone solution (Iintropin AQ)
Trial: 9040450
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 50 mg losartan and 10 mg enalapril
Trial: 3189700
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids only (Control)
Trial: 25530111
Drug: Revexepride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revexepride (0.5 mg, three times daily)
Trial: 22008690
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg intravenously) + 0.25% ropivacaine (2 mL per incision, 6 mL total)
Trial: 22008690
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg intravenously) + 0.5% ropivacaine (2 mL per incision, 6 mL total)
Trial: 22008690
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no analgesics administered)
Trial: 19691368
Drug: Accumulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accumulation of MPAG(t) concentrations from 50 to 150 mg/L
Trial: 19691368
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in plasma albumin concentration from 40 to 30 g/L
Trial: 9635271
Drug: Epsilon aminocaproic
RxNorm normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon aminocaproic acid (EACA) - loading dose 15 mg/kg, continuous infusion 10 mg/kg per hour for 6 hours
Trial: 1392155
Drug: VMMC protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMMC protocol (vindesine, mitoxantrone, mitomycin C) - Group A: vindesine (2.5 mg/m2 day 1 and 8), mitoxantrone (12 mg/m2/day) every 4 weeks, mitomycin C (8 mg/m2) every 8 weeks
Trial: 1392155
Drug: VMMC protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMMC protocol (vindesine, mitoxantrone, mitomycin C) - Group B: vindesine (2.5 mg/m2), mitoxantrone (12 mg/m2) every 3 weeks on day 1, mitomycin C (8 mg/m2) every 6 weeks
Trial: 3912735
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (control side)
Trial: 26673433
Drug: ATX-101 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 (2 mg/cm)
Trial: 19741509
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (ASA)
Trial: 11228032
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management with medication, physiotherapy, or bracing
Trial: 9158511
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg epirubicin in 50 mL normal saline 1-2 weeks after TURBT, repeated for 8 weeks and thereafter monthly for one year
Trial: 9158511
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy after TURBT (control group)
Trial: 8119091
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue (Tissucol) applied as a spray (1 ml) at the end of the operation
Trial: 3116982
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (12.5, 25 and 50 ng/kg/min) during nitrendipine treatment
Trial: 3116982
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (12.5, 25 and 50 ng/kg/min) during placebo
Trial: 352705
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active drug (placebo)
Trial: 15100671
Drug: Desloratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (5 mg)
Trial: 25351788
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g kg(‐1) ammonia chloride (ACD)
Trial: 25351788
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g kg(‐1) calcium carbonate (PLA)
Trial: 21337251
Drug: Spa treatment
RxNorm normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa treatment (combined sauna, cold water immersion, and jacuzzi) after the first match for post-PHV players
Trial: 8160726
Drug: Evaluation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation and treatment of chest pain in patients with angiographically normal coronary arteries
Trial: 2527534
Drug: Cilazapril 5
RxNorm normalized name: cilazapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 5 mg
Trial: 23645534
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with temozolomide or irinotecan
Trial: 16343498
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 400 mcg
Trial: 18068887
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L-Pop (self-etch adhesive)
Trial: 17351746
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg Afimoxifene gel
Trial: 11258646
Drug: Moderate preliminary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate preliminary exercises (approximately 4 mmol/l lactate)
Trial: 7748304
Drug: Serotonin uptake
RxNorm normalized name: Serotonin uptake inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin uptake inhibitors (SUI; e.g., citalopram, fluoxetine)
Trial: 7748304
Drug: m‐CPP (5‐HT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐CPP (5‐HT partial agonist)
Trial: 7748304
Drug: Ondansetron (5‐HT3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (5‐HT3 antagonist, 0.5 mg/day)
Trial: 7748304
Drug: Serotonin uptake
RxNorm normalized name: Serotonin uptake inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin uptake inhibitors (SUI) with brief psychosocial intervention
Trial: 3433871
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg t.i.d. for 2 months
Trial: 26967654
Drug: Recommendations for
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommendations for trial preparation and conduct, including sensitisation meetings led by local leaders, involvement of Health Extension Workers, and use of local analogies for explaining randomisation.
Trial: 16898002
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy of S-1 (80 mg/m2 for 14 days) and docetaxel (DOC) starting at 40 mg/m2, increased to 50 mg/m2 at level 2.
Trial: 10831272
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus immunotherapeutic agents (IFN‐α and/or IL‐2)
Trial: 29939053
Drug: Attachment-Based Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-Based Family Therapy (ABFT)
Trial: 16103515
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose at 2 mg x kg(‐1) x min(‐1)
Trial: 2290270
Drug: Conventional IMN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional IMN tablets (Monisid, Bulgaria)
Trial: 2290270
Drug: Long-acting IMN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting IMN tablets (Olicard, FRG)
Trial: 7338570
Drug: Bumetanide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (various doses in study 1 and 1 or 2 mg in study 2)
Trial: 7338570
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 or 80 mg in study 2)
Trial: 27438319
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of ticagrelor twice daily
Trial: 27438319
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of ticagrelor twice daily
Trial: 25196041
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of nicotine gum
Trial: 16832816
Drug: Bortezomib at
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib at doses of 1.0 mg/m2, 1.3 mg/m2, or 1.5 mg/m2 on Days 1, 4, 8, and 11 of a 21-day treatment cycle for a maximum of 9 cycles
Trial: 16832816
Drug: Bortezomib at
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib at 1.5 mg/m2
Trial: 16832816
Drug: Bortezomib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (all doses)
Trial: 2692653
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant chemotherapy (control group).
Trial: 2692653
Drug: Cyclophosphamide 5
RxNorm normalized name: cyclophosphamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 5 mg/kg/day for six days, given 2-4 weeks after mastectomy (in a parallel study with 110 patients).
Trial: 26491824
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g myo‐inositol, 10 mg monacolin K, 800 mg lipoic acid for 6 months
Trial: 7519976
Drug: Cocaine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 0.4 mg/kg per dose, 10 or 11 doses at 30 min intervals (total dose range 233-408 mg)
Trial: 3512031
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (heparin fragment)
Trial: 15302008
Drug: Tezosentan 1
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan 1 mg/h
Trial: 15302008
Drug: Tezosentan 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan 0.2 mg/h
Trial: 11181472
Drug: Tezosentan 5
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan 5 mg/h
Trial: 11762740
Drug: Milk-based dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based dietary supplements (powder reconstituted in fat-free milk)
Trial: 11762740
Drug: Ready-to-drink milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-drink milk-based supplement
Trial: 11762740
Drug: Low-lactose control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-lactose control preparations
Trial: 9420452
Drug: Low-dose micronutrient
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose micronutrient supplement containing trace minerals (zinc and selenium)
Trial: 19399562
Drug: Topical or
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical or intraductal fibrin glue
Trial: 11560557
Drug: RTV :
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RTV : SQV 200 : 800 mg (E)
Trial: 11560557
Drug: RTV :
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RTV : SQV 400 : 400 mg (B)
Trial: 11560557
Drug: Combination regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimens (E, F, G)
Trial: 23517506
Drug: Intensive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive management (4 weekly review) for 48 weeks
Trial: 23517506
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (12 weekly review) for 48 weeks
Trial: 22051756
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg i.v.) in non-diabetics (n = 20)
Trial: 16778364
Drug: lansoprazole, 30
RxNorm normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole, 30 mg/day